Kelsey S M, Weinhardt B, Pocock C E, Shaw E, Newland A C
Department of Haematology, Royal London Hospital, UK.
J Chemother. 1992 Oct;4(5):281-5. doi: 10.1080/1120009x.1992.11739178.
The efficacy of piperacillin/tazobactam (PIPC/TBT) in combination with gentamicin was assessed as empirical therapy in 44 febrile neutropenic patients with haematological malignancy. A favourable response to therapy was seen in 67% patients overall and in 57% of patients with microbiologically documented infection. PIPC/TBT demonstrated good clinical and in vitro activity against isolated pathogens, particularly Gram positive cocci such as Staphylococcus epidermidis. The MIC of both Gram positive and Gram negative pathogens to PIPC was reduced in the presence of TBT. PIPC/TBT plus gentamicin is a safe and effective combination for empirical therapy in febrile neutropenic patients, even in a unit with a predominance of Gram positive infections.
在44例血液系统恶性肿瘤伴发热性中性粒细胞减少的患者中，评估了哌拉西林/他唑巴坦（PIPC/TBT）联合庆大霉素作为经验性治疗的疗效。总体上67%的患者对治疗反应良好，微生物学确诊感染的患者中57%反应良好。PIPC/TBT对分离出的病原体显示出良好的临床和体外活性，特别是对革兰氏阳性球菌如表皮葡萄球菌。在TBT存在的情况下，革兰氏阳性和革兰氏阴性病原体对PIPC的最低抑菌浓度均降低。PIPC/TBT加庆大霉素是发热性中性粒细胞减少患者经验性治疗的安全有效组合，即使在革兰氏阳性感染占优势的科室也是如此。
